Cargando…

Silmitasertib (CX-4945), a Clinically Used CK2-Kinase Inhibitor with Additional Effects on GSK3β and DYRK1A Kinases: A Structural Perspective

[Image: see text] A clinical casein kinase 2 inhibitor, CX-4945 (silmitasertib), shows significant affinity toward the DYRK1A and GSK3β kinases, involved in down syndrome phenotypes, Alzheimer’s disease, circadian clock regulation, and diabetes. This off-target activity offers an opportunity for stu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grygier, Przemyslaw, Pustelny, Katarzyna, Nowak, Jakub, Golik, Przemyslaw, Popowicz, Grzegorz M., Plettenburg, Oliver, Dubin, Grzegorz, Menezes, Filipe, Czarna, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2023
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10041529/ https://www.ncbi.nlm.nih.gov/pubmed/36883902 http://dx.doi.org/10.1021/acs.jmedchem.2c01887

Ejemplares similares

Validation of an LC–MS/MS Method for the Quantification of the CK2 Inhibitor Silmitasertib (CX-4945) in Human Plasma
por: Schwarz, Rico, et al.
Publicado: (2022)

Binding mechanism and biological effects of flavone DYRK1A inhibitors for the design of new antidiabetics
por: Pustelny, Katarzyna, et al.
Publicado: (2023)

Structural Determinants of CX-4945 Derivatives as Protein Kinase CK2 Inhibitors: A Computational Study
por: Liu, Hongbo, et al.
Publicado: (2011)

Different Persistence of the Cellular Effects Promoted by Protein Kinase CK2 Inhibitors CX-4945 and TDB
por: Girardi, Cristina, et al.
Publicado: (2015)

DYRK1A Kinase Inhibitors Promote β-Cell Survival and Insulin Homeostasis
por: Barzowska, Agata, et al.
Publicado: (2021)

Effects of the CK2 Inhibitors CX-4945 and CX-5011 on Drug-Resistant Cells
por: Zanin, Sofia, et al.
Publicado: (2012)

CX-4945: the protein kinase CK2 inhibitor and anti-cancer drug shows anti-fungal activity
por: Masłyk, Maciej, et al.
Publicado: (2017)

Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice
por: Ferrer-Font, Laura, et al.
Publicado: (2017)

Structural Basis for the Selective Inhibition of Cdc2-Like Kinases by CX-4945
por: Lee, Joo Youn, et al.
Publicado: (2019)

CX-4945 Induces Methuosis in Cholangiocarcinoma Cell Lines by a CK2-Independent Mechanism
por: Lertsuwan, Jomnarong, et al.
Publicado: (2018)

Phosphoproteomic Landscape of AML Cells Treated with the ATP-Competitive CK2 Inhibitor CX-4945
por: Rosales, Mauro, et al.
Publicado: (2021)

Mechanistic Basis for In Vivo Therapeutic Efficacy of CK2 Inhibitor CX-4945 in Acute Myeloid Leukemia
por: Klink, Morgann, et al.
Publicado: (2021)

Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy – potential clinical relevance
por: D’Amore, Claudio, et al.
Publicado: (2020)

Structural analysis of PIM1 kinase complexes with ATP-competitive inhibitors
por: Bogusz, Jozefina, et al.
Publicado: (2017)

The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies
por: Chon, Hae J., et al.
Publicado: (2015)

Preclinical In Vitro and In Vivo Evidence of an Antitumor Effect of CX-4945, a Casein Kinase II Inhibitor, in Cholangiocarcinoma()()()
por: Zakharia, Kais, et al.
Publicado: (2018)

CX-4945 and siRNA-Mediated Knockdown of CK2 Improves Cisplatin Response in HPV(+) and HPV(−) HNSCC Cell Lines
por: Trembley, Janeen H., et al.
Publicado: (2021)

Influence of Casein kinase II inhibitor CX-4945 on BCL6-mediated apoptotic signaling in B-ALL in vitro and in vivo
por: Richter, Anna, et al.
Publicado: (2020)

Inhibition of Casein Kinase II by CX-4945, But Not Yes-associated protein (YAP) by Verteporfin, Enhances the Antitumor Efficacy of Temozolomide in Glioblastoma
por: Liu, Xiangyu, et al.
Publicado: (2019)

Anti-adipogenic and Pro-lipolytic Effects on 3T3-L1 Preadipocytes by CX-4945, an Inhibitor of Casein Kinase 2
por: Yadav, Anil Kumar, et al.
Publicado: (2022)

Identification of a Novel Function of CX-4945 as a Splicing Regulator
por: Kim, Hyeongki, et al.
Publicado: (2014)

MEK Inhibitor PD-0325901 Overcomes Resistance to CK2 Inhibitor CX-4945 and Exhibits Anti-Tumor Activity in Head and Neck Cancer
por: Bian, Yansong, et al.
Publicado: (2015)

CK2 Inhibitor CX-4945 Blocks TGF-β1-Induced Epithelial-to-Mesenchymal Transition in A549 Human Lung Adenocarcinoma Cells
por: Kim, Jiyeon, et al.
Publicado: (2013)

Correction: Lertsuwan et al. CX-4945 Induces Methuosis in Cholangiocarcinoma Cell Lines by a CK2-Independent Mechanism. Cancers 2018, 10, 283
por: Lertsuwan, Jomnarong, et al.
Publicado: (2022)

CK2 inhibition with silmitasertib promotes methuosis-like cell death associated to catastrophic massive vacuolization of colorectal cancer cells
por: Silva-Pavez, Eduardo, et al.
Publicado: (2019)

Crystal structure of a low molecular weight activator Blm-pep with yeast 20S proteasome – insights into the enzyme activation mechanism
por: Witkowska, Julia, et al.
Publicado: (2017)

Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity
por: Quotti Tubi, Laura, et al.
Publicado: (2013)

Inhibitory Response to CK II Inhibitor Silmitasertib and CDKs Inhibitor Dinaciclib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines
por: Ma, Yixuan, et al.
Publicado: (2022)

4,5,7‐Trisubstituted indeno[1,2‐b]indole inhibits CK2 activity in tumor cells equivalent to CX‐4945 and shows strong anti‐migratory effects
por: Birus, Robin, et al.
Publicado: (2021)

Structural Characterization of Glycerol Kinase from the Thermophilic Fungus Chaetomium thermophilum
por: Wilk, Piotr, et al.
Publicado: (2020)

Structural Determinants of Substrate Specificity of SplF Protease from Staphylococcus aureus
por: Stach, Natalia, et al.
Publicado: (2021)

Mutational analysis of two residues in the DYRK homology box of the protein kinase DYRK1A
por: Widowati, Esti Wahyu, et al.
Publicado: (2018)

Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB
por: Buontempo, Francesca, et al.
Publicado: (2015)

How to Catch the Ball: Fullerene Binding to the Corannulene Pincer
por: Menezes, Filipe, et al.
Publicado: (2022)

Acid Rain and Flue Gas: Quantum Chemical Hydrolysis of NO(2)
por: Menezes, Filipe, et al.
Publicado: (2022)

A Buckycatcher in Solution—A Computational Perspective
por: Menezes, Filipe, et al.
Publicado: (2023)

Mirk/dyrk1B Kinase in Ovarian Cancer
por: Friedman, Eileen
Publicado: (2013)

Crystal Structure of Kluyveromyces lactis Glucokinase (KlGlk1)
por: Zak, Krzysztof M., et al.
Publicado: (2019)

Differential maturation and chaperone dependence of the paralogous protein kinases DYRK1A and DYRK1B
por: Papenfuss, Marco, et al.
Publicado: (2022)

Structures of Down Syndrome Kinases, DYRKs, Reveal Mechanisms of Kinase Activation and Substrate Recognition
por: Soundararajan, Meera, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_i3v2t60qap7euu1p0qeiuau2da